(Q33915358)

30 July 2017

1 reference

title

The costs of rheumatoid arthritis: an international long-term view (English)

1 reference

30 July 2017

1 reference

Pugner KM

1

1 reference

30 July 2017

Scott DI

series ordinal

2

1 reference

30 July 2017

Holmes JW

series ordinal

3

1 reference

30 July 2017

Hieke K

series ordinal

4

1 reference

30 July 2017

1 April 2000

1 reference

Seminars in Arthritis and Rheumatism

30 July 2017

1 reference

30 July 2017

29

1 reference

30 July 2017

5

1 reference

30 July 2017

305-320

1 reference

The university rheumatic disease clinic: provider and patient receptions of cost

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Social and economic impacts of four musculoskeletal conditions. A study using national community-based data

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The economic impact of musculoskeletal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The cost of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The costs of rheumatoid arthritis. a patient-oriented study of chronic disease costs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

A multicenter study of annual health service utilization and costs in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Functional improvement and costs of hip and knee arthroplasty in destructive rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Treatment of rheumatoid arthritis--does it affect society's cost for the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

In- and out-patient rehabilitation in rheumatoid arthritis. A controlled, open, longitudinal, cost-effectiveness study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi-Cal program

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Rehabilitation for rheumatoid arthritis patients. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Inpatient rheumatic disease units: are they worth it?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomised controlled clinical and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Are slow-acting anti-rheumatic drugs monitored too often? An audit of current clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Disease-modifying anti-rheumatic drug therapy. An expensive therapy despite inexpensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Clinical economics review: gastrointestinal complications of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Usage of complementary therapies in rheumatology: A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: Comparisons with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: results of a tree structured analysis using RECPAM

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The work dynamics of the person with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Prognosis of functional capacity and work capacity in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Work capacity of patients with inflammatory joint diseases. An eight-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Identification of work disability in rheumatoid arthritis: physical, radiographic and laboratory variables do not add explanatory power to demographic and functional variables

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The underestimated long term medical and economic consequences of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The impact of chronic disease: a sociomedical profile of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The impact of rheumatoid arthritis on the household work performance of women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Expanding the definition of disability: implications for planning, policy, and research

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

The hospital cost of total hip arthroplasty. A comparison between 1981 and 1990

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980017-7

7 January 2021

10.1016/S0049-0172(00)80017-7

Identifiers

DOI

1 reference

30 July 2017

1 reference